GIANT BIOGENE (02367) · Company profile · Eqvero

GIANT BIOGENE

02367HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	5.52 bn CNY	5.54 bn CNY	3.52 bn CNY	2.36 bn CNY	1.55 bn CNY
Cost of revenue	1 bn CNY	942.41 m CNY	542.83 m CNY	341.58 m CNY	173.94 m CNY
Research and development expense	88.79 m CNY	106.5 m CNY	74.97 m CNY	44.04 m CNY	24.95 m CNY
Selling, general and administrative expense	2.22 bn CNY	2.16 bn CNY	1.26 bn CNY	817.44 m CNY	415.66 m CNY
Operating profit after depreciation	2.12 bn CNY	2.28 bn CNY	1.61 bn CNY	1.13 bn CNY	910.57 m CNY
Operating profit before depreciation	2.2 bn CNY	2.33 bn CNY	1.65 bn CNY	1.16 bn CNY	934.78 m CNY
EBIT	2.12 bn CNY	2.28 bn CNY	1.61 bn CNY	1.13 bn CNY	910.57 m CNY
EBITDA	2.2 bn CNY	2.33 bn CNY	1.65 bn CNY	1.16 bn CNY	934.78 m CNY
Interest expense	302 k CNY	239 k CNY	112 k CNY	21 k CNY	—
Profit before tax	2.35 bn CNY	2.46 bn CNY	1.75 bn CNY	1.18 bn CNY	972.92 m CNY
Income tax expense	435.64 m CNY	396.03 m CNY	296.89 m CNY	176.16 m CNY	144.79 m CNY
Income before extraordinary items	1.91 bn CNY	2.06 bn CNY	1.45 bn CNY	1 bn CNY	828.13 m CNY
Common dividends	574.45 m CNY	623.7 m CNY	436.54 m CNY	—	—
Total dividends	574.45 m CNY	623.7 m CNY	436.54 m CNY	306.03 m CNY	19.32 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.